Literature DB >> 9291745

Pathophysiology of the thalassemias. The Albion Walter Hewlett Award presentation.

S L Schrier1.   

Abstract

The Albion Walter Hewlett Award (named for Professor of Medicine and Chair of the Stanford Department of Medicine 1916-1925) recognizes a role model, accomplished in discovery of the biological sciences and at the same time a consummate and compassionate physician. In introductory remarks, Dr. Stanley L. Schrier, Professor of Medicine (Hematology), the tenth recipient of the Award, indicated that the person so identified is no longer a viable model in academic medicine. The loss of this sort of person is serious because this appropriately trained physician-investigator was uniquely positioned to study pathophysiology, defined as the processes by which disordered biology produces disease. He used his own studies on the clinical manifestations of the thalassemias to clarify what he meant by pathophysiology. Thus he and his colleagues first defined membrane material properties of alpha and beta thalassemic RBC membranes and the states of hydration of alpha and beta thalassemic RBC and found them to be strikingly divergent. The biochemical counterparts of these alterations proved to be the accumulation of the excess unmatched partially oxidized globin chains on the membrane skeleton. In vitro studies with chemical oxidants selectively oxidized alpha and beta globin chains which then attached to the RBC membrane skeleton and reproduced the membrane material properties characteristic of beta and alpha thalassemia respectively. Many of these alterations had occurred prior to the reticulocyte stage so that pursuit of pathophysiology shifted to studies of marrow erythroid precursors, and it was shown that in beta thalassemia major there was accelerated programmed cell death as well as defective assembly of the membrane skeleton.

Entities:  

Mesh:

Year:  1997        PMID: 9291745      PMCID: PMC1304431     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  12 in total

1.  Globin-chain specificity of oxidation-induced changes in red blood cell membrane properties.

Authors:  S L Schrier; N Mohandas
Journal:  Blood       Date:  1992-03-15       Impact factor: 22.113

2.  Michael S. Brown, MD and Joseph L. Goldstein, MD. 1985 Nobel laureates in medicine.

Authors:  M S Brown; J L Goldstein
Journal:  J Investig Med       Date:  1996-02       Impact factor: 2.895

3.  Columbia/HCA and the resurgence of the for-profit hospital business. (2)

Authors:  R Kuttner
Journal:  N Engl J Med       Date:  1996-08-08       Impact factor: 91.245

4.  The new health care game.

Authors:  J P Kassirer
Journal:  N Engl J Med       Date:  1996-08-08       Impact factor: 91.245

Review 5.  Ferrokinetics in man.

Authors:  C A Finch; K Deubelbeiss; J D Cook; J W Eschbach; L A Harker; D D Funk; G Marsaglia; R S Hillman; S Slichter; J W Adamson; A Ganzoni; E R Biblett
Journal:  Medicine (Baltimore)       Date:  1970-01       Impact factor: 1.889

6.  The "value added" of not-for-profit health plans.

Authors:  P M Nudelman; L M Andrews
Journal:  N Engl J Med       Date:  1996-04-18       Impact factor: 91.245

7.  Cellular and membrane properties of alpha and beta thalassemic erythrocytes are different: implication for differences in clinical manifestations.

Authors:  S L Schrier; E Rachmilewitz; N Mohandas
Journal:  Blood       Date:  1989-11-01       Impact factor: 22.113

Review 8.  Thalassemia: pathophysiology of red cell changes.

Authors:  S L Schrier
Journal:  Annu Rev Med       Date:  1994       Impact factor: 13.739

9.  Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley's anemia)

Authors:  J Yuan; E Angelucci; G Lucarelli; M Aljurf; L M Snyder; C R Kiefer; L Ma; S L Schrier
Journal:  Blood       Date:  1993-07-15       Impact factor: 22.113

10.  Characterization and comparison of the red blood cell membrane damage in severe human alpha- and beta-thalassemia.

Authors:  R Advani; S Sorenson; E Shinar; W Lande; E Rachmilewitz; S L Schrier
Journal:  Blood       Date:  1992-02-15       Impact factor: 22.113

View more
  4 in total

1.  Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders.

Authors:  Vichai Atichartakarn; Khanchit Likittanasombat; Suporn Chuncharunee; Pakorn Chandanamattha; Surapon Worapongpaiboon; Pantep Angchaisuksiri; Katcharin Aryurachai
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

Review 2.  α-Globin as a molecular target in the treatment of β-thalassemia.

Authors:  Sachith Mettananda; Richard J Gibbons; Douglas R Higgs
Journal:  Blood       Date:  2015-04-13       Impact factor: 22.113

3.  Pleckstrin-2 is essential for erythropoiesis in β-thalassemic mice, reducing apoptosis and enhancing enucleation.

Authors:  Maria Feola; Andrea Zamperone; Daniel Moskop; Huiyong Chen; Carla Casu; Dechen Lama; Julie Di Martino; Mansour Djedaini; Luena Papa; Marc Ruiz Martinez; Tenzin Choesang; Jose Javier Bravo-Cordero; Matthew MacKay; Paul Zumbo; Nathan Brinkman; Charles S Abrams; Stefano Rivella; Shilpa Hattangadi; Christopher E Mason; Ronald Hoffman; Peng Ji; Antonia Follenzi; Yelena Z Ginzburg
Journal:  Commun Biol       Date:  2021-05-03

Review 4.  Ineffective erythropoiesis in β -thalassemia.

Authors:  Jean-Antoine Ribeil; Jean-Benoit Arlet; Michael Dussiot; Ivan Cruz Moura; Geneviève Courtois; Olivier Hermine
Journal:  ScientificWorldJournal       Date:  2013-03-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.